Back to top
more

Avanos Medical (AVNS)

(Delayed Data from NYSE)

$23.02 USD

23.02
255,474

+0.53 (2.36%)

Updated Aug 8, 2024 04:00 PM ET

After-Market: $23.03 +0.01 (0.04%) 5:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (106 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Brookdale (BKD) Q1 Adjusted EBITDA to Beat View, Occupancy Up

Brookdale Senior Living (BKD) witnesses 17 straight months of year-over-year increases in weighted average occupancy level.

Illumina (ILMN) Partners With Henry Ford Health for NGS Test

Illumina (ILMN) collaborates with Henry Ford Health to conduct a series of studies that is likely to focus on the genetic drivers of cardiovascular disease.

Here's Why Investors Should Buy Bio-Rad (BIO) Stock Now

Investors are optimistic about Bio-Rad (BIO) on robust growth in Life Science and Clinical Diagnostics arms.

Thermo Fisher (TMO) Expands to Boost Commercial Manufacturing

Thermo Fisher's expansion in Bourgoin is built on the company's investments in small molecule solutions.

Henry Schein (HSIC) Acquires Majority Stake in Biotech Dental

Henry Schein (HSIC) announces that the completion of the Biotech Dental partnership brings forth the company's several important solutions to customers.

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

Investors are optimistic about IDEXX's (IDXX) strength in the Companion Animal Group business.

CVS Health (CVS) Team Up to Treat Digestive Disorder Virtually

CVS Health's (CVS) recent partnership with Oshi makes it possible for its members to receive coordinated virtual digestive treatment.

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Here's Why You Should Retain McKesson (MCK) Stock for Now

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Quest Diagnostics (DGX) Advances Access to Transplant Services

Quest Diagnostics' (DGX) upgrade to advanced diagnostics and support services is likely to feature personalized patient access to service centers and mobile phlebotomists.

Is Avanos Medical (AVNS) Outperforming Other Medical Stocks This Year?

Here is how Avanos Medical (AVNS) and Becton Dickinson (BDX) have performed compared to their sector so far this year.

QIAGEN's (QGEN) Expanded Test Menu Aids, FX Woe Lingers

In terms of QIAstat-Dx, QIAGEN (QGEN) continues to witness increased demand for system placements and growing consumables usage around the world.

National Vision (EYE) Rides on Comps Growth Amid Macro Issues

National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.

3 Reasons to Add Avanos (AVNS) Stock to Your Portfolio

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

Illumina (ILMN) to Expand Genomics Capacity With New Pact

Illumina's (ILMN) recent collaboration is built on the shared goal of the organizations to expand sequencing capabilities and capacity for all people in Africa.

Here's Why Investors Should Invest in Zimmer Biomet (ZBH) Now

Investors are optimistic about Zimmer Biomet (ZBH) on strong elective procedure recovery and commercial execution.

Illumina's (ILMN) NovaSeq X Exceeds 200 Order Milestone

Illumina's (ILMN) NovaSeq X records the strongest pre-launch demand ever witnessed for any instrument.

3 Reasons to Retain Integer Holdings (ITGR) Stock for Now

Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.

CVS Health's (CVS) New Initiatives Aid, Margin Woes Linger

CVS Health (CVS) launches functionality that gives patients more choices and convenience in filling prescriptions.

Cardiovascular Systems (CSII) Finishes ECLIPSE Trial Enrollment

Cardiovascular Systems' (CSII) ECLIPSE clinical trial data is likely to help physicians form an optimal treatment plan for patients with severely calcified coronary arteries.

Community Health (CYH) Divests Hospital for $92 Million

Community Health (CYH) divests a healthcare facility in West Virginia, thereby reinforcing the sincere focus that it puts to shed non-core assets and use funds to grow well-performing business areas.

LabCorp (LH) Expands Colon Cancer Test Access With New Pact

LabCorp's (LH) at-home collection kit will offer patients an additional and easier option to get screened for colon cancer.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

Investors are upbeat about Haemonetics (HAE) owing to impressive Plasma and Hospital business performance, with continued strength in the Hemostasis Management product line.

3 Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio

Investors are optimistic about AMN Healthcare's (AMN) broad array of services.

Masimo's (MASI) New FDA Clearance to Boost Patient Monitoring

Masimo's (MASI) receipt of the FDA's De Novo grant is expected to combat opioid overdoses by boosting patient monitoring.